Poster Presenter: Dawn Gist, MD, Second-Year Pediatric Rheumatology Fellow, Texas Children’s Hospital/Baylor College of Medicine
Poster Title: Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Poster Session A: 10:30 a.m.–12:30 p.m. on Sunday, October 26
What is your poster about?
“My poster is a retrospective review of pediatric patients who received adalimumab as therapy for a variety of rheumatic conditions and had testing for adalimumab antibodies. We looked at what factors were associated with the development of anti-adalimumab antibodies.”
Why did you decide to investigate this topic?
“I decided to investigate this topic because I am curious why some patients develop anti-adalimumab antibodies and others do not. The development of anti-adalimumab antibodies can lead to decreased efficacy of adalimumab and potential for uncontrolled disease.”
What are you working on next related to this research?
“The next step for this project is to publish the results in a manuscript format to further contribute to public knowledge.”
What excites you most about your work?
“What excites me most about this work is finding correlations in factors associated with antibody development to guide more research to be done on practical applications to prevent development of anti-adalimumab antibodies (such as use of low-dose methotrexate, more frequent dosing, etc).”
What are you most looking forward to at ACR Convergence 2025 in Chicago?
“I am excited to hear the latest news in rheumatology, network with professionals around the world, and spend time exploring Chicago during this year’s ACR conference.”
Don’t Miss a Session
If you can’t make it to a live session during ACR Convergence 2025, make plans to watch the replay. All registered participants receive on-demand access to scientific sessions after the meeting through October 31, 2026.